We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marilyn Ader PhD

Marilyn Ader PhD

Associate Director, Diabetes and Obesity Research Institute; Associate Professor of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California

Marilyn Ader is the Associate Director of the Diabetes and Obesity Research Institute and Associate Professor in the Department of Biomedical Sciences at Cedars-Sinai Medical Center. She is a card-carrying physiologist by training, with early interests in the biologic adaptations that occur with aging.

During her doctoral studies at the University of Southern California, she studied with Dr. Richard Bergman, a pre-eminent engineer who recognized the power of engineering principles of feedback regulation to the investigation of biological questions, specifically the control of the blood sugar. Through this partnership that continues to this day, Dr. Ader has been an essential player in the development and validation of mathematical models that have dramatically altered our understanding of glucose metabolism and its dysregulation in obesity and diabetes.

Through this work, Dr. Ader is recognized worldwide for her expertise in systems physiology and inter-organ crosstalk in the area of carbohydrate metabolism. Dr. Ader has served on or chaired many grant review panels of the NIH as well as the American Diabetes Association and American Heart Association, and she has been PI of projects funded by both the NIH and industry. She is currently involved in both basic science and clinical projects to investigate the metabolic compensations that occur during the development of insulin resistance, and the mechanisms by which inadequate compensation is the critical factor in the pathogenesis of Type 2 diabetes.


Dr. Ader has no relevant disclosures.